87
Participants
Start Date
April 30, 2019
Primary Completion Date
December 10, 2019
Study Completion Date
December 10, 2019
VX-121
Tablets for oral administration.
TEZ
TEZ tablet for oral administration.
VX-561
Tablets for oral administration.
TEZ/IVA
Fixed-dose combination tablets for oral administration.
IVA
Tablets for oral administration.
Placebo
Placebos matched to VX-121, TEZ, and VX-561 for oral administration.
Columbia University Medical Center, New York
Wake Forest University Baptist Medical Center, Winston-Salem
Vanderbilt University Medical Center, Nashville
University of Kentucky., Lexington
Nationwide Children's Hospital, Columbus
University of Minnesota, Minneapolis
Tulane Medical Center, New Orleans
Santiago Reyes, M.D., Oklahoma City
Keck Medical Center of University of Southern California, Los Angeles
Kaiser Permanente, Oakland
Boston Children's Hospital, Boston
University of Texas Health Science Center at San Antonio, San Antonio
Charite Paediatric Pulmonology Department, Berlin
Ruhrlandklinik Westdeutsches Lungenzentrum am Klinikum Essen, Essen
Pneumologisches Studienzentrum Muenchen-West, München
Academic Medical Center, Amsterdam
University Medical Center, Utrecht, Department of Pulmonology and Tuberculosis, Heidelberglaan
UMC St. Radboud, Nijmegen
Erasmus Medical Center, Rotterdam
HagaZiekenhuis van den Haag, The Hague
Hospital de Santa Maria, Lisbon
University Hospitals Birmingham NHS Foundation Trust, Birmingham
Royal Brompton & Harefield NHS Foundation Trust, Royal Brompton Hospital, London
Wythenshawe Hospital, Manchester
The Newcastle upon Tyne Hospitals NHS Foundation Trust, The Royal Victoria Infirmary, Newcastle upon Tyne
All Wales Adult Cystic Fibrosis Centre, University Hospital Llandough, Penarth
Vertex Pharmaceuticals Incorporated
INDUSTRY